The optic nerve transmits visual information from the retina to the brain.
traumatic injuries in the optic nerve, as in the spinal cord and other parts of the central nervous system (CNS), can be associated with axonal drop-out and (RGC) neuron and oligodendrocyte cell death. Macrophages infiltrate the lesion site and phagocytose cell debris, such as degenerated myelin. In response to these events, reactive gliosis occurs, in which neighboring astrocytes undergo hypertrophy and proliferate. On a larger scale, axonal injury and cell death result in a generalized loss of tissue architecture, which can manifest as widespread demyelination, widened subdural spaces, and formation of cystic structures. In non-infectious and infectious inflammatory disorders, liquefactive necrosis of the optic nerve can occur. Over time, glial scars resulting from astrocyte proliferation often fill in the tissue defect.
When injured from these insults, the nerve fibers that comprise the optic nerve, as in other parts of the mammalian CNS, do not efficiently repair themselves or regenerate. Damaged axons from surviving RGCs may initially attempt to arborize, but are inhibited from doing so by a variety Nanomedicine and Optic Nerve Regeneration-Implications for Ophthalmology of cell intrinsic and extrinsic factors, including the presence of myelinassociated inhibitory proteins and traversing a dense glial scar. 8, 9 Without the ability to reach their axonal targets, neurons lose their neurotrophic support (protein growth factors) and die. 10 New approaches to enhance CNS repair remain important clinical goals in regenerative medicine.
Nanomedicine
One of the most exciting emerging therapeutic strategies to promote optic nerve (and CNS) regeneration is nanomedicine. Nanomedicine uses the production, assembly, and control of structures, devices, or molecules less than 100 nanometers (nm) in size to treat disease. The dimensions of nanoscale materials are particularly amenable to treatment of optic nerve neuropathies because they can penetrate intracellularly and be fabricated into dimensions mimicking the extracellular matrix (ECM) (e.g. collagen,
laminin, fibronectin) disrupted in CNS injury (resulting from axonal dropout, demyelination, apoptosis, necrosis, and glial scarring).
Nanoscaffolds
One experimental approach involves engineering a variety of socalled nanofiber scaffolds for transplantation into the CNS. Prefabricated nanofiber scaffolds can be constructed ex vivo by a method known as electrospinning. In this technique, a polymer or composite material is extruded out of a thin syringe at a constant rate in the presence of a strong electrical field. Electrostatic forces 'stretch and whip' the electrified jet of polymer to form aligned or non-aligned fibers with nanoscale diameters.
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Popular biodegradable materials used to fabricate these scaffolds include poly(lactic-co-glycolic acid) (PLGA), poly(L-lactide-co-epsilon-caprolactone) (PLCL) and poly(L-lactic acid) (PLLA). 12 These fibers have been used as a substrate for neural cells, where their growth in vitro more closely models 3D growth seen in vivo than standard 2D culture. 13 The combination of nanofibers coated with proteins has been shown to promote nerve regeneration in recent studies. Polymers can be mixed with neurotrophic proteins to generate coupled growth factorencapsulated fibers with defined protein release kinetics. Recent in vivo transplantation of a glial-derived neurotrophic factor (GDNF)-nanofiber composite scaffold into transected rat sciatic nerve (peripheral nervous system) showed accelerated histologic regeneration of the nerve, increased myelinated axons, and improved electrophysiologic function.
14 In a study involving optic nerve injury, a polymer composed of polyglycolic acid (PGA, synthetic) and chitosan (a natural material derived from the exoskeleton of crustaceans), was coated with a recombinant neuronal adhesion protein called L1. This molecule is expressed on elongating axons of CNS neurons during development and regeneration. 15 An earlier study demonstrated that rats treated with soluble L1 following spinal cord injury achieve some degree of locomotor recovery. 16 L1-coated PGA-chitosan conduits were placed to bridge transected optic nerve stumps in vivo and compared with non-L1-coated PGA-chitosan, and showed less macrophage invasion and improved axonal re-growth and myelination. 17 Furthermore, the protein-coated nanofibers promoted more RGC axon regeneration, as shown by retrograde labeling from the superior colliculus, than nanofibers without L1 coating. 17 While this particular study did not address functional visual recovery, it showed that the regenerated axons align along the proteincoated nanofibers and that the nanofiber conduit was absorbed and degraded in two months without significant local toxicity. Most importantly, 75% of the SAPNS-treated adult animals showed return of functional orienting movement, as assayed by the ability to turn to a small object, whereas all the sham-treated controls remained blind.
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Nanosphere Delivery of Therapeutic Agents
Glaucoma is associated with increased IOP, and the reduction of IOP can slow the progression of glaucomatous optic neuropathy. 19, 20 To this end, The study showed that while all three constructs transfected cells, only PCEP and magnetic nanoparticles did not induce an inflammatory response and, of the two, magnetic nanoparticles had a superior transfection rate. 23 One can imagine delivering genes encoding for neurotrophic proteins to RGCs and other retinal neurons and glia to enhance ganglion cell survival.
Nanomedicine Adjuncts to Surgery
Nanomedicine may also have application in surgical therapy of glaucomatous optic neuropathy. Currently, in patients with poor
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Nanoparticle Tagging
The transplantation of neural stem and other precursor cells represents a promising strategy for cell therapy of CNS diseases, including retinal degenerations, spinal cord injury, and Parkinson's disease. [25] [26] [27] Ideally, the transplanted cells mature into photoreceptors, oligodendrocytes, and dopaminergic neurons that replace the endogenous cell types lost in these diseases; however, their therapeutic effect may also be exerted through 
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Modulating the activity of antioxidant enzymes in animal models has been shown to protect RGCs in a specific type of glaucoma and Leber's optic neuropathy and reduce demyelination in optic neuritis. [35] [36] [37] Rareearth cerium nanoparticles (called 'nanoceria'), some 5nm in diameter, exhibit a high affinity to scavenge ROS. Importantly, intravitreal injection of nanoceria protects and rescues photoreceptors from light-induced degeneration, as assayed by calculating rates of photoreceptor apoptosis and by electroretinography. 38 It will be interesting to determine whether nanoceria exert a protective effect on RGCs and oligodendrocytes in glaucoma, optic neuritis, and mitochondrial or other optic neuropathies.
Conclusion
The translation of nanotechnology to therapy has been eagerly pursued. response. 39 Future studies will require rigorous testing of these and other, novel nanoscale materials in a variety of animal models (not solely rodents) to ensure that the therapeutic benefits of nanomedicine will be optimized and predictable and not be outweighed by toxic side effects.
Despite these concerns, nanomedicine represents a promising and diverse modality for a variety of human disorders, and may have a special place in the treatment of eye diseases. From the transplantation of nanofibers and ROS-scavenging nanomaterials to nanosphere delivery of drugs and trophic proteins, nanomedicine offers multipronged strategies for the treatment of optic neuropathies. n
